Erratum for

• PSMA-Directed Imaging and Therapy of Salivary Gland Tumors: A Single-Center Retrospective Study.

  Civan C, Kasper S, Berliner C, Fragoso-Costa P, Grünwald V, Pogorzelski M, Schaarschmidt BM, Lang S, Kersting D, Nader M, Lückerath K, Herrmann K, Fendler WP, Weber M. Civan C, et al. J Nucl Med. 2023 Mar;64(3):372-378. doi: 10.2967/jnumed.122.264342. Epub 2022 Sep 22. J Nucl Med. 2023. PMID: 36137757 Free PMC article.
• Prediction of Resistance to ¹⁷⁷Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers.

  Sartor O, Ledet E, Huang M, Schwartz J, Lieberman A, Lewis B, Layton J, Barata P, Jang A, Hawkins M, Pocha O, Lanka S, Harris K. Sartor O, et al. J Nucl Med. 2023 Nov;64(11):1721-1725. doi: 10.2967/jnumed.123.266167. Epub 2023 Sep 28. J Nucl Med. 2023. PMID: 37770113
• Long-Term Nephrotoxicity of ¹⁷⁷Lu-PSMA Radioligand Therapy.

  Steinhelfer L, Lunger L, Cala L, Pfob CH, Lapa C, Hartrampf PE, Buck AK, Schäfer H, Schmaderer C, Tauber R, Brosch-Lenz J, Haller B, Meissner VH, Knorr K, Weber WA, Eiber M. Steinhelfer L, et al. J Nucl Med. 2024 Jan 2;65(1):79-84. doi: 10.2967/jnumed.123.265986. J Nucl Med. 2024. PMID: 37857504
• Dosimetry of [¹⁷⁷Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis.

  Ells Z, Grogan TR, Czernin J, Dahlbom M, Calais J. Ells Z, et al. J Nucl Med. 2024 Aug 1;65(8):1264-1271. doi: 10.2967/jnumed.124.267452. J Nucl Med. 2024. PMID: 38960712 Free PMC article.